Takeda stops development of prostate cancer drug TAK-700

TAK-700 (orteronel) is an inhibitor of testosterone biosynthesis (a sterol 17,20-lyase inhibitor). Results in phase III tests were disappointing.

Takeda news release, June 19, 2014